P30 CA138292/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1977	1
1979	1
2010	3
2011	9
2012	19
2013	27
2014	57
2015	78
2016	88
2017	83
2018	78
2019	95
2020	124
2021	116
2022	104
2023	100
2024	69
2025	30

1

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.

Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Chmielecki J, et al. Nat Commun. 2023 Feb 27;14(1):1070. doi: 10.1038/s41467-023-35961-y. Nat Commun. 2023. PMID: 36849494 Free PMC article.

2

Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts.

Zhang B, Liu M, Mai F, Li X, Wang W, Huang Q, Du X, Ding W, Li Y, Barwick BG, Ni JJ, Osunkoya AO, Chen Y, Zhou W, Xia S, Dong JT. Zhang B, et al. J Clin Invest. 2024 May 23;134(14):e175949. doi: 10.1172/JCI175949. J Clin Invest. 2024. PMID: 38781024 Free PMC article.

3

MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.

Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, Wang X, Frye SV, Behera M, Schneider F, Ramalingam SS, Owonikoko T, Earp HS, DeRyckere D, Graham DK. Yan D, et al. J Clin Invest. 2022 Aug 1;132(15):e150517. doi: 10.1172/JCI150517. J Clin Invest. 2022. PMID: 35708914 Free PMC article.

4

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.

Kansal V, Burnham AJ, Kinney BLC, Saba NF, Paulos C, Lesinski GB, Buchwald ZS, Schmitt NC. Kansal V, et al. J Immunother Cancer. 2023 Jan;11(1):e005940. doi: 10.1136/jitc-2022-005940. J Immunother Cancer. 2023. PMID: 36650022 Free PMC article.

5

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.

Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC, Shepherd FA, Bulusu KC, Laus G, Collins B, Barrett JC, Hartmaier RJ, Papadimitrakopoulou V. Chmielecki J, et al. Nat Commun. 2023 Feb 27;14(1):1071. doi: 10.1038/s41467-023-35962-x. Nat Commun. 2023. PMID: 36849516 Free PMC article.

6

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.

Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Qian DC, et al. Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.

7

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.

Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. Maithel SK, et al. Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27. Ann Surg Oncol. 2023. PMID: 37368098 Free PMC article. Clinical Trial.

8

Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.

Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes BF. Akce M, et al. J Immunother Cancer. 2023 Oct;11(10):e007235. doi: 10.1136/jitc-2023-007235. J Immunother Cancer. 2023. PMID: 37852737 Free PMC article. Clinical Trial.

9

The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export.

Tripathi BK, Hirsh NH, Qian X, Durkin ME, Wang D, Papageorge AG, Lake R, Evrard YA, Marcus AI, Ramalingam SS, Dasso M, Vousden KH, Doroshow JH, Walters KJ, Lowy DR. Tripathi BK, et al. Nat Cancer. 2024 Dec;5(12):1902-1918. doi: 10.1038/s43018-024-00847-5. Epub 2024 Nov 11. Nat Cancer. 2024. PMID: 39528835 Free PMC article.

10

Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.

Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu C, Li X, Wu D, Xia S, Chen J, Qian WP, Yang L, Osunkoya AO, Boise L, Vertino PM, Zhao Y, Li M, Chen HR, Kowalski J, Kucuk O, Zhou W, Dong JT. Zhang B, et al. Nat Commun. 2021 Mar 17;12(1):1714. doi: 10.1038/s41467-021-21976-w. Nat Commun. 2021. PMID: 33731701 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

936 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

936 results

Results by year